Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate-to-severe Ulcerative Colitis

NCT06867094 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06867094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06867094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate-to-severe Ulcerative Colitis
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 28, 2025
Completion date
October 14, 2026
Enrollment
204 (estimated)
Sites
117

Conditions

As the registry lists them; a condition with its own page is linked.

colitis ulcerative